Target Research Guide

CB2, explained simply with PubMed links

This page translates CB2 research into plain English: what scientists studied, what kind of evidence exists, where the source links are strong or limited, and which PubMed records support each bucket.

Launch set page

Read Evidence Overview Open Source Table

196research sources

60evidence buckets

PubMedlinked references

What this page is

A plain-English research page about CB2. It explains what researchers studied and links the PubMed or DOI sources.

How to use it

Read the overview first. If a sentence matters to you, open the PubMed link or source table below it.

Important limit

This page is education, not medical advice, dosing advice, or a recommendation to use cannabinoids.

Evidence Rows 269

Traceable statements carried into the source table.

Human Evidence 0

Rows where human participants, patients, or clinical evidence are visible.

Mechanisms 104

Biology, target, enzyme, receptor, or pharmacology rows.

Safety / Limits 16

Safety, tolerability, uncertainty, or insufficient-evidence context.

Evidence Overview

CB2 has research behind it, but the bucket matters.

This page currently indexes 196 research sources across 60 evidence bucket(s). Read it as a map of what researchers have studied, not as a single bottom-line instruction. PMID 39288632

Human evidence 0 evidence rows

Human studies are separated from preclinical and mechanistic evidence so a reader can see where people were actually studied. PMID 39288632

Mechanisms 104 evidence rows

Mechanistic rows explain biological plausibility, receptor activity, enzyme activity, or pharmacology; they do not automatically prove an outcome in people. PMID 39288632

Safety and limits 16 evidence rows

Safety, tolerability, product quality, impairment, interactions, and higher-risk contexts stay visible instead of being treated as footnotes. PMID 39288632

Evidence Buckets

What the CB2 research is usually about

Jump to source-backed table

CB2

CB2 appears in rows about CB2 mechanisms. It currently draws from 37 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 39288632

CB2

CB2 appears in rows about CB2 mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

CB2

CB2 appears in rows about CB2 mechanisms. It currently draws from 11 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 17828291

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

CB2 appears in rows studying 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 9 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 26271952

Receptor, target, metabolic, and pharmacology mechanisms

CB2 appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 9 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 39598860

receptor, transporter, target, metabolic, or pharmacology mechanisms

CB2 appears in rows about receptor, transporter, target, metabolic, or pharmacology mechanisms mechanisms. It currently draws from 7 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 40967679

Reader Map

Evidence buckets before the source table

Grouped for readability

Bucket	Plain-English meaning	Evidence posture	Starting source
CB2	Grouped source-backed rows focused on CB2, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (13), mechanistic or pharmacological (24)	PMID 39288632
CB2	Grouped source-backed rows focused on CB2, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (6)	PMID 12505686
CB2	Grouped source-backed rows focused on CB2, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (7)	PMID 17828291
2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Grouped source-backed rows focused on 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (3), preclinical (1)	PMID 26271952
Receptor, target, metabolic, and pharmacology mechanisms	Grouped source-backed rows focused on Receptor, target, metabolic, and pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (4)	PMID 39598860
receptor, transporter, target, metabolic, or pharmacology mechanisms	Grouped source-backed rows focused on receptor, transporter, target, metabolic, or pharmacology mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)	PMID 40967679
anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Grouped source-backed rows focused on anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)	PMID 36150527
CB1	Grouped source-backed rows focused on CB1, collapsed into one reader-facing bucket before the full source table.	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)	PMID 12505686

Safety Reading Notes

Read safety context beside the research guide.

The CB2 source set includes safety-context rows around 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 39288632

Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (3), preclinical (1)

PubMed For Dummies Article

CB2 Evidence Review: the long-form source walk-through

Quick read

CB2 currently has 269 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 39288632
The evidence classes most visible in the row language are insufficient (152), mechanistic or pharmacological (106), preclinical (10), and preliminary human (1). PMID 39598860
The study-design language most visible in the row language is Narrative or expert review (138), Animal study (76), Cellular or in vitro study (32), and other mapped categories (8). PMID 40270953
The repeated topics are CB2 (63), receptor, target, metabolic, or pharmacology mechanisms (26), receptor, target, or pharmacology mechanisms (14), CB1 (14), and other mapped categories (152), which tells the reader where to start opening PubMed and DOI links. PMID 32899626

Start with the research question

CB2 is built from 269 source-backed evidence row(s) and 196 research source(s). The current evidence classes read as insufficient (152), mechanistic or pharmacological (106), preclinical (10), and preliminary human (1), and the study-design language most often reads as Narrative or expert review (138), Animal study (76), Cellular or in vitro study (32), and other mapped categories (8). PMID 39288632

The row-level question is not simply whether CB2 is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB2 (63), receptor, target, metabolic, or pharmacology mechanisms (26), receptor, target, or pharmacology mechanisms (14), CB1 (14), and other mapped categories (152). PMID 12505686

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 30627539

Preclinical evidence 8 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 30405366

Mechanistic evidence 104 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 42196303

Limits and uncertainty 168 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 33230154

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 36916438

Where this page has the most source density

The largest bucket surfaced for this page is CB2. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB2, which gives readers another way to see what the literature repeatedly circles. PMID 39288632

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 12505686

Bucket chapters: what the literature is circling

CB2

37 research sources 37 rows (864-925) Mechanistic research summary: insufficient (13), mechanistic or pharmacological (24)

CB2 appears in rows about CB2 mechanisms. It currently draws from 37 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 39288632

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39288632

Evidence row 864
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 39288632
Evidence row 925
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, mic... PMID 41740200

CB2

12 research sources 12 rows (868-917) Mechanistic research summary: insufficient (6), mechanistic or pharmacological (6)

CB2 appears in rows about CB2 mechanisms. It currently draws from 12 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 12505686

Evidence row 868
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, sele... PMID 12505686
Evidence row 917
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuro... PMID 24877594

CB2

11 research sources 11 rows (863-922) Mechanistic research summary: insufficient (4), mechanistic or pharmacological (7)

CB2 appears in rows about CB2 mechanisms. It currently draws from 11 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 17828291

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 17828291

Evidence row 863
THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or s... PMID 17828291
Evidence row 922
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tiss... PMID 18247131

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

9 research sources 9 rows (1078-1091) Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (3), preclinical (1)

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 26271952

Evidence row 1078
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharma... PMID 26271952
Evidence row 1091
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure:... PMID 38052772

Receptor, target, metabolic, and pharmacology mechanisms

9 research sources 9 rows (563-579) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (4)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39598860

Evidence row 563
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: rece... PMID 39598860
Evidence row 579
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 41155621

receptor, transporter, target, metabolic, or pharmacology mechanisms

7 research sources 7 rows (663-679) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40967679

Evidence row 663
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, met... PMID 40967679
Evidence row 679
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: recep... PMID 23373571

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

6 research sources 6 rows (1063-1076) Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)

CB2 appears in rows studying anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 6 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 36150527

Evidence row 1063
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 36150527
Evidence row 1076
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biolog... PMID 23512546

CB1

6 research sources 6 rows (814-849) Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)

CB2 appears in rows about CB1 mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 12505686

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 12505686

Evidence row 814
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or s... PMID 12505686
Evidence row 849
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain,... PMID 31461639

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (104 row(s)), and safety/tolerability context (16 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 39288632

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 12505686

What this does and does not mean

It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 34179865
It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 17828291
It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 25220897

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 39288632

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 12505686

Source-reading checklist for CB2

Open the linked PubMed or DOI record. PMID 33636308
Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 18537620
Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 30670965
Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 28826536
Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 30767756

Source Notes

CB2 source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

Evidence row 31
CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 38
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 40270953
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
Evidence row 39
THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 43
CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 30627539
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.
Evidence row 44
THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological (outcome measure: safety, effect, or mechanism claims). PMID 30405366
Evidence class: mechanistic or pharmacological. Source: Cannabis Therapeutics and the Future of Neurology.
Evidence row 79
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 80
THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 174
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 203
CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 34179865
Evidence class: preclinical; Study design: Human clinical study. Source: Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
Evidence row 204
THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 205
THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 25220897
Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Evidence row 206
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39288632
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).
Evidence row 207
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33636308
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Oxa-adamantyl cannabinoids.
Evidence row 208
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 18537620
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Evidence row 210
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30670965
Evidence class: insufficient; Study design: Narrative or expert review. Source: Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.
Evidence row 211
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 28826536
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Evidence row 212
Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30767756
Evidence class: insufficient; Study design: Narrative or expert review. Source: New Insights in Cannabinoid Receptor Structure and Signaling.
Evidence row 213
THC modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 30550613
Evidence class: preclinical; Study design: Animal study. Source: Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.
Evidence row 214
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 216
THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 238
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33897066
Evidence class: preliminary human; Study design: Human clinical study. Source: Adverse Effects of Recreational and Medical Cannabis.
Evidence row 242
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 42076122
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.
Evidence row 253
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084
Evidence class: insufficient; Study design: Animal study. Source: Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
Evidence row 254
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 23924692
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Evidence row 256
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
Evidence row 258
Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263
Evidence class: insufficient; Study design: Systematic review. Source: Cys-loop receptors on cannabinoids: All high?
Evidence row 261
CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736
Evidence class: preclinical; Study design: Animal study. Source: Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
Evidence row 274
Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 39334169
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.
Evidence row 275
Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 37164044
Evidence class: insufficient; Study design: Narrative or expert review. Source: CB2 receptor in the CNS: From immune and neuronal modulation to behavior.
Evidence row 276
Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 16596771
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor signaling.
Evidence row 288
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 289
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 26271952
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System and its Modulation by Phytocannabinoids.
Evidence row 292
CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 17965195
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
Evidence row 294
THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics). PMID 17704824
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
Evidence row 303
THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 20047159
Evidence class: insufficient; Study design: Narrative or expert review. Source: FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Evidence row 307
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39245706
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.
Evidence row 309
THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 39747798
Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical Probes for Investigating the Endocannabinoid System.
Evidence row 313
Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms). PMID 30075103
Evidence class: preclinical; Study design: Animal study. Source: Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Evidence row 340
CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 41008526
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.
Evidence row 343
Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns). PMID 33909195
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.
Evidence row 357
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 361
CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 362
THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 440
THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 33228239
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
Evidence row 475
THC studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 31332738
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of Medical Cannabis.
Evidence row 514
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns). PMID 27428345
Evidence class: insufficient; Study design: Narrative or expert review. Source: [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].
Evidence row 517
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 518
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 36424484
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.
Evidence row 519
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 520
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 521
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 10036999
Evidence class: insufficient; Study design: Narrative or expert review. Source: The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.
Evidence row 523
CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 38673788
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
Evidence row 529
CBN studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 38673788
Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
Evidence row 533
CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes). PMID 40568800
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.
Evidence row 535
CBN studied for Pain-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes). PMID 36424484
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.
Evidence row 540
CBG studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 541
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 548
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40540228
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
Evidence row 552
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 40326034
Evidence class: insufficient; Study design: Animal study. Source: Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.
Evidence row 557
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36497400
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.
Evidence row 558
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 563
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 568
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 569
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 570
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25269802
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Evidence row 571
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42105814
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
Evidence row 572
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40540228
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
Evidence row 573
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40326034
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.
Evidence row 577
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 579
CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41155621
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.
Evidence row 584
CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes). PMID 39598860
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.
Evidence row 589
CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 23415610
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.
Evidence row 591
CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 36615835
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
Evidence row 593
CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes). PMID 35614947
Evidence class: insufficient; Study design: Narrative or expert review. Source: Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action.
Evidence row 607
CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 620
CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 621
CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 622
CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 42105814
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.
Evidence row 627
CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.
Evidence row 646
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 648
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns). PMID 42352060
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.
Evidence row 663
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40967679
Evidence class: insufficient; Study design: Meta-analysis or systematic evidence synthesis. Source: Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
Evidence row 664
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 667
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 671
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 31368508
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
Evidence row 674
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 40790027
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.
Evidence row 675
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 39137108
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.
Evidence row 679
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms). PMID 23373571
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.
Evidence row 686
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 691
CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 692
CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 694
CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 40046175
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacology of Cannabinoids in Chronic Pain.
Evidence row 704
CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 36916438
Evidence class: preclinical; Study design: Animal study. Source: The antinociceptive activity and mechanism of action of cannabigerol.
Evidence row 711
CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes). PMID 35628241
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.
Evidence row 736
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 40270953
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.
Evidence row 740
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 756
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 31549358
Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Evidence row 760
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 761
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42196303
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
Evidence row 763
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 764
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 766
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
Evidence row 767
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25257544
Evidence class: insufficient; Study design: Systematic review. Source: Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
Evidence row 768
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16205722
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
Evidence row 769
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28087250
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoids in the treatment of epilepsy.
Evidence row 770
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41008636
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.
Evidence row 771
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30170189
Evidence class: mechanistic or pharmacological. Source: Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.
Evidence row 772
THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 31454413
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
Evidence row 784
THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 788
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes). PMID 31454413
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
Evidence row 796
THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 32899626
Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
Evidence row 798
THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 33230154
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Evidence row 806
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 33636308
Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Oxa-adamantyl cannabinoids.
Evidence row 807
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 18537620
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Evidence row 808
THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 814
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 817
Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 10469884
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid receptor ligands.
Evidence row 825
THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31968549
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
Evidence row 832
THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 26132518
Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Cannabinoids.
Evidence row 836
Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40521518
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.
Evidence row 839
Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 30767756
Evidence class: insufficient; Study design: Narrative or expert review. Source: New Insights in Cannabinoid Receptor Structure and Signaling.
Evidence row 842
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 34050525
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.
Evidence row 843
THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 27086601
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid System: A Multi-Facet Therapeutic Target.
Evidence row 846
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 16570099
Evidence class: insufficient; Study design: Narrative or expert review. Source: The pharmacology of cannabinoid receptors and their ligands: an overview.
Evidence row 847
Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 19939187
Evidence class: insufficient; Study design: Narrative or expert review. Source: Latest advances in cannabinoid receptor agonists.
Evidence row 849
Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 31461639
Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
Evidence row 863
THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 17828291
Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Evidence row 864
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 39288632
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).
Evidence row 865
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 18537620
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Evidence row 866
THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 26698193
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Introduction to the Endogenous Cannabinoid System.
Evidence row 867
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 31368508
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabichromene is a cannabinoid CB2 receptor agonist.
Evidence row 868
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 869
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 10469884
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid receptor ligands.
Evidence row 870
THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 33811300
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Evidence row 871
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 40271066
Evidence class: mechanistic or pharmacological. Source: A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.
Evidence row 872
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 28826535
Evidence class: insufficient; Study design: Narrative or expert review. Source: Functional Selectivity at Cannabinoid Receptors.
Evidence row 873
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 9336020
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid CB1 and CB2 receptors.
Evidence row 874
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 26124120
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
Evidence row 875
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 34684770
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Spicy Story of Cannabimimetic Indoles.
Evidence row 876
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 30639103
Evidence class: mechanistic or pharmacological. Source: Crystal Structure of the Human Cannabinoid Receptor CB2.
Evidence row 877
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 32004460
Evidence class: mechanistic or pharmacological. Source: Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.
Evidence row 878
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 28220706
Evidence class: mechanistic or pharmacological. Source: Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
Evidence row 879
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36889269
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes.
Evidence row 880
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 33749323
Evidence class: mechanistic or pharmacological. Source: CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.
Evidence row 881
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 11514083
Evidence class: mechanistic or pharmacological. Source: CB2 cannabinoid receptor-mediated peripheral antinociception.
Evidence row 882
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 27215781
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
Evidence row 883
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16563625
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor mediation of antinociception.
Evidence row 884
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36058263
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice.
Evidence row 885
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 34774714
Evidence class: mechanistic or pharmacological. Source: Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation.
Evidence row 886
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 27608434
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.
Evidence row 887
THC modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 20849866
Evidence class: mechanistic or pharmacological. Source: The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
Evidence row 888
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36922494
Evidence class: mechanistic or pharmacological. Source: Structural basis of selective cannabinoid CB2 receptor activation.
Evidence row 889
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 38886185
Evidence class: insufficient; Study design: Narrative or expert review. Source: Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).
Evidence row 890
Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16678907
Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
Evidence row 891
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 37349984
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation.
Evidence row 892
Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 36028971
Evidence class: insufficient; Study design: Narrative or expert review. Source: Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.
Evidence row 893
THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 29980914
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
Evidence row 894
Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms). PMID 16596776
Evidence class: insufficient; Study design: Narrative or expert review. Source: Structural requirements for cannabinoid receptor probes.
Evidence row 895
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39334169
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.
Evidence row 896
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 19152719
Evidence class: insufficient; Study design: Narrative or expert review. Source: Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.
Evidence row 897
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 38662453
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease.
Evidence row 898
Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 22197668
Evidence class: insufficient; Study design: Narrative or expert review. Source: CB₂: therapeutic target-in-waiting.
Evidence row 899
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39173999
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation.
Evidence row 900
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39264450
Evidence class: insufficient; Study design: Narrative or expert review. Source: Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.
Evidence row 901
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 36475439
Evidence class: mechanistic or pharmacological. Source: Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.
Evidence row 902
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 37061199
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.
Evidence row 903
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18615177
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.
Evidence row 904
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 30666359
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice.
Evidence row 905
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 29794855
Evidence class: insufficient; Study design: Narrative or expert review. Source: An overview of the cannabinoid type 2 receptor system and its therapeutic potential.
Evidence row 906
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 37286073
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.
Evidence row 907
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 26824325
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.
Evidence row 908
Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 23960212
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.
Evidence row 909
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 38751621
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro.
Evidence row 910
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 20236042
Evidence class: insufficient; Study design: Narrative or expert review. Source: The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.
Evidence row 911
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 12823482
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.
Evidence row 912
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 30414958
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.
Evidence row 913
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 36583304
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.
Evidence row 914
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41875735
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.
Evidence row 915
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40332343
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.
Evidence row 916
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41383775
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.
Evidence row 917
Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 24877594
Evidence class: insufficient; Study design: Narrative or expert review. Source: What we know and do not know about the cannabinoid receptor 2 (CB2).
Evidence row 918
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40791361
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases.
Evidence row 919
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40943579
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders.
Evidence row 920
2-AG modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 16086683
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.
Evidence row 921
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41310604
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization.
Evidence row 922
THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18247131
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.
Evidence row 923
Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 32471272
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
Evidence row 924
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39538989
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling.
Evidence row 925
Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41740200
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.
Evidence row 926
Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 28826536
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Evidence row 927
THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 929
Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35862111
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.
Evidence row 932
Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 26669245
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
Evidence row 933
Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 27835801
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor ligand bias: implications in the central nervous system.
Evidence row 934
Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 20370712
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
Evidence row 935
CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 35083862
Evidence class: insufficient; Study design: Narrative or expert review. Source: A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).
Evidence row 936
CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17704827
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
Evidence row 938
THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17876300
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55: a new member of the cannabinoid receptor clan?
Evidence row 939
THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 20298715
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological characterization of GPR55, a putative cannabinoid receptor.
Evidence row 940
CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology). PMID 17876302
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The orphan receptor GPR55 is a novel cannabinoid receptor.
Evidence row 944
Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 28826536
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.
Evidence row 945
Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 27835801
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor ligand bias: implications in the central nervous system.
Evidence row 947
Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 34676329
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Gynecological Diseases.
Evidence row 948
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 42114685
Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.
Evidence row 949
THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29902723
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.
Evidence row 952
Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29098189
Evidence class: insufficient; Study design: Narrative or expert review. Source: An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.
Evidence row 955
CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 20346144
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.
Evidence row 956
CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 22834922
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration.
Evidence row 962
CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 24751709
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.
Evidence row 971
THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 972
THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 973
THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 16596770
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
Evidence row 977
OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 17906678
Evidence class: insufficient; Study design: Narrative or expert review. Source: Novel cannabinoid receptors.
Evidence row 980
Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 36222019
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid signaling in microglia.
Evidence row 989
THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 990
THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 1004
THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1006
THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 27498155
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
Evidence row 1014
Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 26845556
Evidence class: insufficient; Study design: Systematic review. Source: A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders.
Evidence row 1016
THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1024
Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 29470146
Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
Evidence row 1026
Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 41802611
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.
Evidence row 1030
THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 30697147
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
Evidence row 1031
CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 1032
THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 34259916
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in the landscape of cancer.
Evidence row 1037
THC modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 39368566
Evidence class: mechanistic or pharmacological. Source: Identification of the TRPA1 cannabinoid-binding site.
Evidence row 1039
THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 28120232
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
Evidence row 1040
Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 21727026
Evidence class: insufficient; Study design: Narrative or expert review. Source: G-protein coupled receptors regulating cough.
Evidence row 1041
Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology). PMID 25065940
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Evidence row 1048
CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 35483477
Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological effects of cannabidiol by transient receptor potential channels.
Evidence row 1051
CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 25269802
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Evidence row 1052
CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 40540228
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.
Evidence row 1055
Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29470146
Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
Evidence row 1056
THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 28120232
Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Targets of the Phytocannabinoids: A Complex Picture.
Evidence row 1063
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36150527
Evidence class: insufficient; Study design: Narrative or expert review. Source: Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.
Evidence row 1064
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 27516570
Evidence class: insufficient; Study design: Narrative or expert review. Source: Metabolism of endocannabinoids.
Evidence row 1067
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 34126378
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.
Evidence row 1068
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 25461979
Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid metabolism by cytochrome P450 monooxygenases.
Evidence row 1072
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 35986066
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB1 receptors regulate salivation.
Evidence row 1076
Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23512546
Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical probes of endocannabinoid metabolism.
Evidence row 1078
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26271952
Evidence class: insufficient; Study design: Narrative or expert review. Source: The Endocannabinoid System and its Modulation by Phytocannabinoids.
Evidence row 1080
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12505686
Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
Evidence row 1081
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 16678907
Evidence class: insufficient; Study design: Narrative or expert review. Source: Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
Evidence row 1085
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24768821
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
Evidence row 1086
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36966972
Evidence class: insufficient; Study design: Narrative or expert review. Source: Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.
Evidence row 1087
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 36125319
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: 2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.
Evidence row 1088
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33450278
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.
Evidence row 1090
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24676249
Evidence class: insufficient; Study design: Narrative or expert review. Source: Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.
Evidence row 1091
2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 38052772
Evidence class: preclinical; Study design: Animal study. Source: A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.
Evidence row 1109
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 40563990
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.
Evidence row 1113
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 25463999
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Protective effect of palmitoylethanolamide in a rat model of cystitis.
Evidence row 1117
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 27720681
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.
Evidence row 1118
PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 28336953
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor.
Evidence row 1123
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10469890
Evidence class: insufficient; Study design: Narrative or expert review. Source: The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?
Evidence row 1124
Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 18514375
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of the CB1 receptor in the regulation of sleep.
Evidence row 1134
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 24644287
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Evidence row 1142
NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 33568652
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.
Evidence row 1146
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12432948
Evidence class: insufficient; Study design: Narrative or expert review. Source: The cannabinoid receptors.
Evidence row 1147
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17698254
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
Evidence row 1150
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15901805
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Evidence row 1152
Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15148262
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
Evidence row 1157
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17876300
Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55: a new member of the cannabinoid receptor clan?
Evidence row 1158
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 18514375
Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of the CB1 receptor in the regulation of sleep.
Evidence row 1160
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12023533
Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Evidence row 1162
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32696508
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria.
Evidence row 1165
Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23789792
Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Mechanism of platelet activation induced by endocannabinoids in blood and plasma.
Evidence row 1180
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 30070030
Evidence class: insufficient. Source: Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.
Evidence row 1183
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 26707833
Evidence class: mechanistic or pharmacological. Source: Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.
Evidence row 1197
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms). PMID 23813098
Evidence class: insufficient; Study design: Narrative or expert review. Source: Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.

Source Trail

Source-backed evidence table and references

196 research sources

This section is the technical source layer under the overview. It keeps grouped evidence buckets, evidence rows, PubMed or DOI links, related pages, and references visible for audit and revision.

Plain-Language Summary

CB2 is a cannabinoid-relevant target page. The current evidence ledger links it to 269 evidence row(s) from 196 source(s), mostly framed as insufficient (152), mechanistic or pharmacological (106), preclinical (10), preliminary human (1).

Identity

Canonical name: cb2
Type: biological target
Subtype: canonical_cannabinoid_receptor
Description: Not recorded

Evidence Snapshot

Evidence rows: 269
Sources: 196
Evidence classes: insufficient (152), mechanistic or pharmacological (106), preclinical (10), preliminary human (1)
Draft sections: mechanistic evidence (104), preclinical evidence (8), safety (16), uncertainty (141)

Key Draft Sections

Safety and tolerability: 16 evidence row(s).
Uncertainty and gaps: 141 evidence row(s).
Preclinical evidence: 8 evidence row(s).
Mechanistic evidence: 104 evidence row(s).

Ligands And Modulators

Subject	Relationship	Object Or Focus	Evidence Summary	Sources	Evidence Rows
2-AG	studied for	2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic and preclinical research summary: insufficient (5), mechanistic or pharmacological (3), preclinical (1)	9	9 rows (1078-1091)
2-AG	modulates	CB2	Mechanistic research summary: mechanistic or pharmacological (1)	1	920
Anandamide	studied for	anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (2)	6	6 rows (1063-1076)
Anandamide	modulates	CB2	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (890-894)
Cannabinoids	studied for	Cannabinoids and immune modulation research outcomes	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (1)	3	3 rows (274-276)
Cannabinoids	modulates	CB1	Mapped evidence with interpretation limits: insufficient (4)	4	4 rows (806-839)
Cannabinoids	modulates	CB2	Mechanistic research summary: insufficient (13), mechanistic or pharmacological (24)	37	37 rows (864-925)
Cannabinoids	modulates	GPR18	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (944-945)
Cannabinoids	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (4)	4	4 rows (926-934)
Cannabinoids	modulates	receptor, target, or pharmacology mechanisms	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (1)	5	5 rows (206-212)
Cannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	242
Cannabinoids	modulates	TRPA1	Mapped evidence with interpretation limits: insufficient (1)	1	1040
Cannabinoids	modulates	TRPM8	Mapped evidence with interpretation limits: insufficient (1)	1	1055
Cannabinoids	modulates	TRPV3	Mapped evidence with interpretation limits: insufficient (1)	1	1014
Cannabinoids	modulates	TRPV4	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (1024-1026)
CBC	studied for	Pain-related outcomes	Mechanistic and preclinical research summary: insufficient (2), mechanistic or pharmacological (1), preclinical (1)	4	4 rows (686-694)
CBC	modulates	receptor, transporter, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (4)	7	7 rows (663-679)
CBC	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Preclinical research summary: insufficient (1), preclinical (1)	2	2 rows (646-648)
CBC	studied for	Skin and inflammatory dermatology	Mechanistic and preclinical research summary: mechanistic or pharmacological (1), preclinical (1)	2	2 rows (704-711)
CBD	studied for	Endocannabinoids and endocannabinoid-like lipids research topics	Mechanistic research summary: mechanistic or pharmacological (1)	1	292
CBD	modulates	GPR18	Mechanistic research summary: mechanistic or pharmacological (3)	3	3 rows (955-962)
CBD	modulates	GPR55	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (2)	3	3 rows (935-940)
CBD	modulates	receptor, target, or pharmacology mechanisms	Mechanistic and preclinical research summary: insufficient (2), mechanistic or pharmacological (1), preclinical (1)	4	4 rows (253-261)
CBD	studied for	safety, risk, adverse-event, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	340
CBD	modulates	TRP channel activity or ionotropic cannabinoid target mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	361
CBD	modulates	TRPA1	Mapped evidence with interpretation limits: insufficient (1)	1	1031
CBD	modulates	TRPM8	Mapped evidence with interpretation limits: insufficient (1)	1	1048
CBDA	studied for	nausea-related or inflammation-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	43
CBDV	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Preclinical research summary: preclinical (1)	1	203
CBG	studied for	Appetite and metabolic outcomes	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	4	4 rows (620-627)
CBG	studied for	Inflammation-related outcomes	Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)	4	4 rows (584-593)
CBG	studied for	Pain-related outcomes	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (31-540)
CBG	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (4)	9	9 rows (563-579)
CBG	studied for	safety, adverse-event, impairment, or formulation-specific concerns	Preclinical research summary: preclinical (1)	1	174
CBG	studied for	safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (1)	5	5 rows (541-558)
CBG	studied for	Skin and inflammatory dermatology	Preclinical research summary: preclinical (1)	1	607
CBG	modulates	TRPM8	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (1051-1052)
CBN	studied for	Pain-related outcomes	Mapped evidence with interpretation limits: insufficient (1)	1	535
CBN	modulates	receptor, target, metabolic, or pharmacology mechanisms	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)	6	6 rows (517-523)
CBN	studied for	safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns	Mapped evidence with interpretation limits: insufficient (1)	1	514
CBN	studied for	Skin and inflammatory dermatology	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (529-533)
Endocannabinoids	modulates	CB1	Mechanistic research summary: insufficient (5), mechanistic or pharmacological (1)	6	6 rows (814-849)
Endocannabinoids	modulates	CB2	Mechanistic research summary: insufficient (6), mechanistic or pharmacological (6)	12	12 rows (868-917)
Endocannabinoids	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Mechanistic and preclinical research summary: mechanistic or pharmacological (1), preclinical (1)	2	2 rows (307-313)
Endocannabinoids	modulates	GPR18	Mapped evidence with interpretation limits: insufficient (3)	3	3 rows (947-952)
Endocannabinoids	modulates	GPR55	Mapped evidence with interpretation limits: insufficient (1)	1	929
Endocannabinoids	modulates	receptor, target, or pharmacology mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (210-258)
Endocannabinoids	studied for	safety, risk, adverse-event, or formulation-specific concerns	Early human research summary: insufficient (1), preliminary human (1)	2	2 rows (238-343)
Endocannabinoids	modulates	TRPA1	Mechanistic research summary: mechanistic or pharmacological (1)	1	1041
Endocannabinoids	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	980
LEA	studied for	LEA biology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)	2	2 rows (1180-1183)
NADA	studied for	NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (2)	2	2 rows (1134-1142)
Noladin ether	studied for	noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms	Mechanistic research summary: insufficient (1), mechanistic or pharmacological (3)	4	4 rows (1146-1152)
OEA	modulates	TRPV1	Mapped evidence with interpretation limits: insufficient (1)	1	977
Oleamide	studied for	oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (1123-1124)
PEA	studied for	PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms	Mechanistic research summary: mechanistic or pharmacological (4)	4	4 rows (1109-1118)
SEA	studied for	SEA biology, metabolism, physiology, or safety-relevant mechanisms	Mapped evidence with interpretation limits: insufficient (1)	1	1197
THC	modulates	CB1	Mechanistic research summary: insufficient (3), mechanistic or pharmacological (1)	4	4 rows (808-843)
THC	modulates	CB2	Mechanistic research summary: insufficient (4), mechanistic or pharmacological (7)	11	11 rows (863-922)
THC	modulates	endocannabinoid enzyme activity or metabolic mechanisms	Mapped evidence with interpretation limits: insufficient (2)	2	2 rows (303-309)
...	...	...	...	...	23 more bucket(s)

Source-Backed Evidence Table

Evidence Row	Statement	Source
31	CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
38	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
39	THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
43	CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes).	Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.PubMed 30627539 DOI 10.1155/2018/1691428
44	THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological (outcome measure: safety, effect, or mechanism claims).	Cannabis Therapeutics and the Future of Neurology.PubMed 30405366 DOI 10.3389/fnint.2018.00051
79	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: appetite-related or metabolic outcomes).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
80	THCV studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related or metabolic outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
174	CBG studied for safety, adverse-event, impairment, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, adverse-event, impairment, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
203	CBDV modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
204	THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
205	THC modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.PubMed 25220897 DOI 10.1016/j.drugalcdep.2014.08.005
206	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
207	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms).	Oxa-adamantyl cannabinoids.PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
208	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
210	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.PubMed 30670965 DOI 10.3389/fphar.2018.01496
211	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
212	Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	New Insights in Cannabinoid Receptor Structure and Signaling.PubMed 30767756 DOI 10.2174/1874467212666190215112036
213	THC modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.PubMed 30550613 DOI 10.1167/iovs.18-24838
214	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
216	THCV modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
238	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: preliminary human (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Human clinical study; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
242	Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.PubMed 42076122 DOI 10.3390/pharmaceutics18040469
253	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.PubMed 33522084 DOI 10.1111/ejn.15134
254	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.PubMed 23924692 DOI 10.1016/j.neuropharm.2013.07.024
256	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabidiol: Pharmaceutical formulations and biomedical applications.PubMed 42212209 DOI 10.22038/ijbms.2026.89134.19592
258	Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms).	Cys-loop receptors on cannabinoids: All high?PubMed 36439263 DOI 10.3389/fphys.2022.1044575
261	CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms).	Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.PubMed 22585736 DOI 10.1084/jem.20120242
274	Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes).	Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.PubMed 39334169 DOI 10.1186/s12974-024-03221-5
275	Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes).	CB2 receptor in the CNS: From immune and neuronal modulation to behavior.PubMed 37164044 DOI 10.1016/j.neubiorev.2023.105226
276	Cannabinoids studied for Cannabinoids and immune modulation research outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Cannabinoids and immune modulation research outcomes).	Cannabinoid receptor signaling.PubMed 16596771 DOI 10.1007/3-540-26573-2_2
288	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
289	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	The Endocannabinoid System and its Modulation by Phytocannabinoids.PubMed 26271952 DOI 10.1007/s13311-015-0374-6
292	CBD studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.PubMed 17965195 DOI 10.1124/mol.107.041863
294	THC studied for Endocannabinoids and endocannabinoid-like lipids research topics; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: Endocannabinoids and endocannabinoid-like lipids research topics).	Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.PubMed 17704824 DOI 10.1038/sj.bjp.0707423
303	THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.PubMed 20047159
307	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.PubMed 39245706 DOI 10.1186/s12974-024-03213-5
309	THC modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Chemical Probes for Investigating the Endocannabinoid System.PubMed 39747798 DOI 10.1007/7854_2024_563
313	Endocannabinoids modulates endocannabinoid enzyme activity or metabolic mechanisms; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: endocannabinoid enzyme activity or metabolic mechanisms).	Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
340	CBD studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.PubMed 41008526 DOI 10.3390/biom15091219
343	Endocannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, risk, adverse-event, or formulation-specific concerns).	Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.PubMed 33909195 DOI 10.1007/s11033-021-06366-1
357	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
361	CBD modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
362	THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
440	THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes).	Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.PubMed 33228239 DOI 10.3390/biom10111575
475	THC studied for Pain-related outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: pain-related outcomes).	Pharmacology of Medical Cannabis.PubMed 31332738 DOI 10.1007/978-3-030-21737-2_8
514	CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns).	[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
517	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
518	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
519	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
520	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
521	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.PubMed 10036999 DOI 10.3109/10428199809059244
523	CBN modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.PubMed 38673788 DOI 10.3390/ijms25084204
529	CBN studied for Skin and inflammatory dermatology; evidence class: insufficient (study design: Narrative or expert review; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.PubMed 38673788 DOI 10.3390/ijms25084204
533	CBN studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, inflammatory, or immune-modulation outcomes).	Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.PubMed 40568800 DOI 10.1021/acs.jmedchem.5c00938
535	CBN studied for Pain-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: pain-related outcomes).	Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
540	CBG studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
541	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
548	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.PubMed 40540228 DOI 10.1021/acs.jmedchem.4c03220
552	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.PubMed 40326034 DOI 10.2174/0115701638363093250324035540
557	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.PubMed 36497400 DOI 10.3390/cancers14235918
558	CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
563	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
568	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
569	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
570	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
571	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
572	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.PubMed 40540228 DOI 10.1021/acs.jmedchem.4c03220
573	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.PubMed 40326034 DOI 10.2174/0115701638363093250324035540
577	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
579	CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.PubMed 41155621 DOI 10.3390/ph18101508
584	CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes).	Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
589	CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.PubMed 23415610 DOI 10.1016/j.bcp.2013.01.017
591	CBG studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.PubMed 36615835 DOI 10.3390/nu15010178
593	CBG studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or immune outcomes).	Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action.PubMed 35614947 DOI 10.3389/fphar.2022.908198
607	CBG studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
620	CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
621	CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
622	CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
627	CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes).	Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.PubMed 36397993 DOI 10.1155/2022/3336516
646	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
648	CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns).	Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
663	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Meta-analysis or systematic evidence synthesis; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
664	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
667	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
671	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
674	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.PubMed 40790027 DOI 10.1038/s41420-025-02674-8
675	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.PubMed 39137108 DOI 10.1089/can.2023.0212
679	CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, transporter, target, metabolic, or pharmacology mechanisms).	The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.PubMed 23373571 DOI 10.1111/bph.12120
686	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
691	CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
692	CBC studied for Pain-related outcomes; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: pain-related outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
694	CBC studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
704	CBC studied for Skin and inflammatory dermatology; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
711	CBC studied for Skin and inflammatory dermatology; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: skin, dermatology, antimicrobial, or topical inflammatory outcomes).	Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
736	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
740	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
756	THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns).	Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.PubMed 31549358 DOI 10.1007/s40263-019-00664-w
760	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
761	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
763	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
764	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
766	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
767	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.PubMed 25257544 DOI 10.1111/bph.12944
768	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.PubMed 16205722 DOI 10.1038/sj.bjp.0706414
769	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
770	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.PubMed 41008636 DOI 10.3390/biom15091329
771	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.PubMed 30170189 DOI 10.1016/j.phrs.2018.08.021
772	THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms).	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
784	THCV studied for Inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: inflammation-related or immune outcomes).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
788	THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: neurobehavioral, cognition, mood, reward, or THC-interaction outcomes).	Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
796	THCV studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes).	It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
798	THCV studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes).	In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
806	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Oxa-adamantyl cannabinoids.PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
807	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
808	THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
814	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
817	Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Pharmacology of cannabinoid receptor ligands.PubMed 10469884
825	THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.PubMed 31968549 DOI 10.3390/molecules25020417
832	THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Synthetic Cannabinoids.PubMed 26132518 DOI 10.1097/maj.0000000000000466
836	Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms).	Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.PubMed 40521518 DOI 10.1021/acsomega.4c11355
839	Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	New Insights in Cannabinoid Receptor Structure and Signaling.PubMed 30767756 DOI 10.2174/1874467212666190215112036
842	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.PubMed 34050525 DOI 10.1007/s43440-021-00270-y
843	THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Endocannabinoid System: A Multi-Facet Therapeutic Target.PubMed 27086601 DOI 10.2174/1574884711666160418105339
846	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
847	Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Latest advances in cannabinoid receptor agonists.PubMed 19939187 DOI 10.1517/13543770903436505
849	Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms).	Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.PubMed 31461639 DOI 10.1016/j.ejphar.2019.172628
863	THC modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
864	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
865	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
866	THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
867	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
868	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
869	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Pharmacology of cannabinoid receptor ligands.PubMed 10469884
870	THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.PubMed 33811300 DOI 10.1007/s12272-021-01326-6
871	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.PubMed 40271066 DOI 10.3389/fphar.2025.1469986
872	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Functional Selectivity at Cannabinoid Receptors.PubMed 28826535 DOI 10.1016/bs.apha.2017.03.005
873	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Pharmacology of cannabinoid CB1 and CB2 receptors.PubMed 9336020 DOI 10.1016/s0163-7258(97
874	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.PubMed 26124120 DOI 10.1073/pnas.1503395112
875	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The Spicy Story of Cannabimimetic Indoles.PubMed 34684770 DOI 10.3390/molecules26206190
876	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Crystal Structure of the Human Cannabinoid Receptor CB2.PubMed 30639103 DOI 10.1016/j.cell.2018.12.011
877	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.PubMed 32004460 DOI 10.1016/j.cell.2020.01.007
878	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.PubMed 28220706 DOI 10.1021/acschemneuro.7b00003
879	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes.PubMed 36889269
880	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.PubMed 33749323 DOI 10.1152/ajprenal.00065.2021
881	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor-mediated peripheral antinociception.PubMed 11514083 DOI 10.1016/s0304-3959(01
882	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.PubMed 27215781 DOI 10.1080/13543776.2016.1193157
883	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	CB2 cannabinoid receptor mediation of antinociception.PubMed 16563625 DOI 10.1016/j.pain.2005.12.018
884	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice.PubMed 36058263 DOI 10.1016/j.lfs.2022.120928
885	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation.PubMed 34774714 DOI 10.1016/j.neuroscience.2021.11.007
886	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.PubMed 27608434 DOI 10.1016/j.eplepsyres.2016.08.011
887	THC modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.PubMed 20849866 DOI 10.1016/j.neuropharm.2010.09.004
888	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Structural basis of selective cannabinoid CB2 receptor activation.PubMed 36922494 DOI 10.1038/s41467-023-37112-9
889	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).PubMed 38886185 DOI 10.1080/13543776.2024.2368745
890	Anandamide modulates CB2; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
891	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation.PubMed 37349984 DOI 10.1111/bph.16172
892	Endocannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.PubMed 36028971 DOI 10.2174/0929867329666220825161603
893	THC modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.PubMed 29980914 DOI 10.1007/164_2018_143
894	Anandamide modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms).	Structural requirements for cannabinoid receptor probes.PubMed 16596776 DOI 10.1007/3-540-26573-2_7
895	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.PubMed 39334169 DOI 10.1186/s12974-024-03221-5
896	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.PubMed 19152719 DOI 10.1017/s1462399409000957
897	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease.PubMed 38662453 DOI 10.1172/jci175205
898	Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	CB₂: therapeutic target-in-waiting.PubMed 22197668 DOI 10.1016/j.pnpbp.2011.12.001
899	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation.PubMed 39173999 DOI 10.1016/j.lfs.2024.123002
900	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.PubMed 39264450 DOI 10.1007/s00213-024-06683-w
901	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.PubMed 36475439 DOI 10.1098/rspb.2022.1941
902	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.PubMed 37061199 DOI 10.1016/j.bbr.2023.114439
903	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.PubMed 18615177 DOI 10.2174/157015907780866884
904	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice.PubMed 30666359 DOI 10.1007/s00213-019-5166-y
905	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	An overview of the cannabinoid type 2 receptor system and its therapeutic potential.PubMed 29794855 DOI 10.1097/aco.0000000000000616
906	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.PubMed 37286073 DOI 10.1016/j.neuropharm.2023.109601
907	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.PubMed 26824325 DOI 10.18632/oncotarget.7042
908	Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.PubMed 23960212 DOI 10.1093/cercor/bht202
909	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro.PubMed 38751621 DOI 10.1021/acsptsci.4c00014
910	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.PubMed 20236042 DOI 10.2174/187152410790780145
911	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.PubMed 12823482 DOI 10.1046/j.1460-9568.2003.02704.x
912	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.PubMed 30414958 DOI 10.1016/j.jpain.2018.10.007
913	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.PubMed 36583304 DOI 10.1002/ptr.7710
914	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.PubMed 41875735 DOI 10.1016/j.phymed.2026.158068
915	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.PubMed 40332343 DOI 10.3390/ijms26083720
916	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.PubMed 41383775 DOI 10.1101/2025.11.26.690750
917	Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	What we know and do not know about the cannabinoid receptor 2 (CB2).PubMed 24877594 DOI 10.1016/j.smim.2014.04.002
918	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases.PubMed 40791361 DOI 10.1101/2025.07.11.664477
919	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders.PubMed 40943579 DOI 10.3390/ijms26178657
920	2-AG modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.PubMed 16086683 DOI 10.1111/j.1471-4159.2005.03380.x
921	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization.PubMed 41310604 DOI 10.1186/s12903-025-07176-8
922	THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.PubMed 18247131 DOI 10.1007/s11481-007-9077-z
923	Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?PubMed 32471272 DOI 10.3390/ijms21113809
924	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling.PubMed 39538989 DOI 10.1093/jleuko/qiae246
925	Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms).	Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.PubMed 41740200 DOI 10.1016/j.molpha.2026.100102
926	Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
927	THC modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
929	Endocannabinoids modulates GPR55; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
932	Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	GPR55 - a putative "type 3" cannabinoid receptor in inflammation.PubMed 26669245 DOI 10.1515/jbcpp-2015-0080
933	Cannabinoids modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Cannabinoid receptor ligand bias: implications in the central nervous system.PubMed 27835801 DOI 10.1016/j.coph.2016.10.005
934	Cannabinoids modulates GPR55; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?PubMed 20370712 DOI 10.2174/156802610791164229
935	CBD modulates GPR55; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).PubMed 35083862 DOI 10.1111/bcpt.13710
936	CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.PubMed 17704827 DOI 10.1038/sj.bjp.0707419
938	THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	GPR55: a new member of the cannabinoid receptor clan?PubMed 17876300 DOI 10.1038/sj.bjp.0707464
939	THC modulates GPR55; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	Pharmacological characterization of GPR55, a putative cannabinoid receptor.PubMed 20298715 DOI 10.1016/j.pharmthera.2010.02.004
940	CBD modulates GPR55; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR55 receptor activity, binding, signaling, or pharmacology).	The orphan receptor GPR55 is a novel cannabinoid receptor.PubMed 17876302 DOI 10.1038/sj.bjp.0707460
944	Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
945	Cannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoid receptor ligand bias: implications in the central nervous system.PubMed 27835801 DOI 10.1016/j.coph.2016.10.005
947	Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoids in Gynecological Diseases.PubMed 34676329 DOI 10.1159/000499164
948	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.PubMed 42114685 DOI 10.1016/j.bcp.2026.118038
949	THC modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.PubMed 29902723 DOI 10.1016/j.ejmech.2018.05.050
952	Endocannabinoids modulates GPR18; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.PubMed 29098189 DOI 10.1089/can.2017.0036
955	CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.PubMed 20346144 DOI 10.1186/1471-2202-11-44
956	CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration.PubMed 22834922 DOI 10.1186/1750-2187-7-10
962	CBD modulates GPR18; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology).	Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.PubMed 24751709 DOI 10.1016/j.ejphar.2014.03.055
971	THC modulates TRPV1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
972	THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
973	THC modulates TRPV1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
977	OEA modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Novel cannabinoid receptors.PubMed 17906678 DOI 10.1038/sj.bjp.0707481
980	Endocannabinoids modulates TRPV1; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: TRPV1 channel activity, desensitization, binding, signaling, or pharmacology).	Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
989	THC modulates TRPV2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
990	THC modulates TRPV2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPV2 channel activity, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
1004	THC modulates TRPV3; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1006	THCV modulates TRPV3; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
1014	Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology).	A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders.PubMed 26845556 DOI 10.2174/1568026616666160204121039
1016	THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1024	Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.PubMed 29470146 DOI 10.1152/ajpgi.00013.2018
1026	Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology).	Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.PubMed 41802611 DOI 10.1016/j.freeradbiomed.2026.02.059
1030	THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
1031	CBD modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
1032	THC modulates TRPA1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
1037	THC modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Identification of the TRPA1 cannabinoid-binding site.PubMed 39368566 DOI 10.1016/j.phrs.2024.107444
1039	THC modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Molecular Targets of the Phytocannabinoids: A Complex Picture.PubMed 28120232 DOI 10.1007/978-3-319-45541-9_4
1040	Cannabinoids modulates TRPA1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	G-protein coupled receptors regulating cough.PubMed 21727026 DOI 10.1016/j.coph.2011.06.005
1041	Endocannabinoids modulates TRPA1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPA1 channel activity, desensitization, binding, signaling, or pharmacology).	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.PubMed 25065940 DOI 10.1016/j.bmc.2014.07.006
1048	CBD modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
1051	CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
1052	CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.PubMed 40540228 DOI 10.1021/acs.jmedchem.4c03220
1055	Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.PubMed 29470146 DOI 10.1152/ajpgi.00013.2018
1056	THC modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology).	Molecular Targets of the Phytocannabinoids: A Complex Picture.PubMed 28120232 DOI 10.1007/978-3-319-45541-9_4
1063	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
1064	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Metabolism of endocannabinoids.PubMed 27516570 DOI 10.5604/17322693.1213898
1067	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.PubMed 34126378 DOI 10.1016/j.plefa.2021.102311
1068	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Endocannabinoid metabolism by cytochrome P450 monooxygenases.PubMed 25461979 DOI 10.1016/j.prostaglandins.2014.11.002
1072	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Cannabinoid CB1 receptors regulate salivation.PubMed 35986066 DOI 10.1038/s41598-022-17987-2
1076	Anandamide studied for anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Chemical probes of endocannabinoid metabolism.PubMed 23512546 DOI 10.1124/pr.112.006387
1078	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The Endocannabinoid System and its Modulation by Phytocannabinoids.PubMed 26271952 DOI 10.1007/s13311-015-0374-6
1080	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
1081	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
1085	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.PubMed 24768821 DOI 10.1016/j.exger.2014.04.008
1086	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.PubMed 36966972 DOI 10.1016/j.pharmthera.2023.108394
1087	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.PubMed 36125319 DOI 10.1111/acer.14949
1088	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.PubMed 33450278 DOI 10.1016/j.neuropharm.2021.108450
1090	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.PubMed 24676249 DOI 10.1039/c4cs00047a
1091	2-AG studied for 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: 2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.PubMed 38052772 DOI 10.1038/s41467-023-43606-3
1109	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.PubMed 40563990 DOI 10.3390/biomedicines13061271
1113	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Protective effect of palmitoylethanolamide in a rat model of cystitis.PubMed 25463999 DOI 10.1016/j.juro.2014.11.083
1117	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.PubMed 27720681 DOI 10.1016/j.ejphar.2016.10.005
1118	PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms).	Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor.PubMed 28336953 DOI 10.1038/s41598-017-00342-1
1123	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?PubMed 10469890
1124	Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms).	The role of the CB1 receptor in the regulation of sleep.PubMed 18514375 DOI 10.1016/j.pnpbp.2008.04.008
1134	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.PubMed 24644287 DOI 10.1074/jbc.m113.536953
1142	NADA studied for NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: NADA biology, receptor or TRP-channel pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.PubMed 33568652 DOI 10.1038/s41467-021-20946-6
1146	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The cannabinoid receptors.PubMed 12432948 DOI 10.1016/s0090-6980(02
1147	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.PubMed 17698254 DOI 10.1016/j.neuint.2007.06.033
1150	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.PubMed 15901805 DOI 10.1124/jpet.105.085282
1152	Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.PubMed 15148262 DOI 10.1038/sj.bjp.0705789
1157	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	GPR55: a new member of the cannabinoid receptor clan?PubMed 17876300 DOI 10.1038/sj.bjp.0707464
1158	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	The role of the CB1 receptor in the regulation of sleep.PubMed 18514375 DOI 10.1016/j.pnpbp.2008.04.008
1160	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.PubMed 12023533 DOI 10.1124/jpet.301.3.1020
1162	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria.PubMed 32696508 DOI 10.1002/jcp.29949
1165	Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms).	Mechanism of platelet activation induced by endocannabinoids in blood and plasma.PubMed 23789792 DOI 10.3109/09537104.2013.803530
1180	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.PubMed 30070030 DOI 10.1002/oby.22245
1183	LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: LEA biology, metabolism, physiology, or safety-relevant mechanisms).	Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.PubMed 26707833 DOI 10.1016/j.phrs.2015.12.009
1197	SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: SEA biology, metabolism, physiology, or safety-relevant mechanisms).	Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.PubMed 23813098 DOI 10.1007/s12035-013-8487-6

2-AG
Anandamide
Appetite and metabolic outcomes
CB1
CBC
CBD
CBDA
CBDV
CBG
CBN
Cannabinoids
Endocannabinoids
GPR18
GPR55
Inflammation-related outcomes
LEA
NADA
Noladin ether
OEA
Oleamide

References

Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.PubMed 39598860 DOI 10.3390/molecules29225471
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.PubMed 40270953 DOI 10.3934/neuroscience.2025003
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.PubMed 32899626 DOI 10.3390/molecules25184036
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.PubMed 30627539 DOI 10.1155/2018/1691428
Cannabis Therapeutics and the Future of Neurology.PubMed 30405366 DOI 10.3389/fnint.2018.00051
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.PubMed 42196303 DOI 10.3390/ijms27104321
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.PubMed 33230154 DOI 10.1038/s41598-020-77175-y
The antinociceptive activity and mechanism of action of cannabigerol.PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.PubMed 17828291 DOI 10.1038/sj.bjp.0707442
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.PubMed 25220897 DOI 10.1016/j.drugalcdep.2014.08.005
Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
Oxa-adamantyl cannabinoids.PubMed 33636308 DOI 10.1016/j.bmcl.2021.127882
Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.PubMed 18537620 DOI 10.2174/092986708784567716
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.PubMed 30670965 DOI 10.3389/fphar.2018.01496
Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.PubMed 28826536 DOI 10.1016/bs.apha.2017.04.004
New Insights in Cannabinoid Receptor Structure and Signaling.PubMed 30767756 DOI 10.2174/1874467212666190215112036
Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.PubMed 30550613 DOI 10.1167/iovs.18-24838
Cannabinoid Ligands Targeting TRP Channels.PubMed 30697147 DOI 10.3389/fnmol.2018.00487
Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
Adverse Effects of Recreational and Medical Cannabis.PubMed 33897066 DOI 10.64719/pb.4395
Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.PubMed 42076122 DOI 10.3390/pharmaceutics18040469
Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.PubMed 33522084 DOI 10.1111/ejn.15134
Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.PubMed 23924692 DOI 10.1016/j.neuropharm.2013.07.024
Cannabidiol: Pharmaceutical formulations and biomedical applications.PubMed 42212209 DOI 10.22038/ijbms.2026.89134.19592
Cys-loop receptors on cannabinoids: All high?PubMed 36439263 DOI 10.3389/fphys.2022.1044575
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.PubMed 22585736 DOI 10.1084/jem.20120242
Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.PubMed 39334169 DOI 10.1186/s12974-024-03221-5
CB2 receptor in the CNS: From immune and neuronal modulation to behavior.PubMed 37164044 DOI 10.1016/j.neubiorev.2023.105226
Cannabinoid receptor signaling.PubMed 16596771 DOI 10.1007/3-540-26573-2_2
An Introduction to the Endogenous Cannabinoid System.PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
The Endocannabinoid System and its Modulation by Phytocannabinoids.PubMed 26271952 DOI 10.1007/s13311-015-0374-6
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.PubMed 17965195 DOI 10.1124/mol.107.041863
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.PubMed 17704824 DOI 10.1038/sj.bjp.0707423
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.PubMed 20047159
Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.PubMed 39245706 DOI 10.1186/s12974-024-03213-5
Chemical Probes for Investigating the Endocannabinoid System.PubMed 39747798 DOI 10.1007/7854_2024_563
Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.PubMed 30075103 DOI 10.1016/j.bcp.2018.07.042
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.PubMed 41008526 DOI 10.3390/biom15091219
Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.PubMed 33909195 DOI 10.1007/s11033-021-06366-1
Pharmacological effects of cannabidiol by transient receptor potential channels.PubMed 35483477 DOI 10.1016/j.lfs.2022.120582
Cannabinoids in the landscape of cancer.PubMed 34259916 DOI 10.1007/s00432-021-03710-7
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.PubMed 33228239 DOI 10.3390/biom10111575
Pharmacology of Medical Cannabis.PubMed 31332738 DOI 10.1007/978-3-030-21737-2_8
[Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].PubMed 27428345
Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
Cannabinoid receptor 2 (Cb2r) mediates cannabinol (CBN) induced developmental defects in zebrafish.PubMed 36424484 DOI 10.1038/s41598-022-23495-0
Pharmacological actions of cannabinoids.PubMed 16596770 DOI 10.1007/3-540-26573-2_1
Molecular Pharmacology of Phytocannabinoids.PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis.PubMed 10036999 DOI 10.3109/10428199809059244
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.PubMed 38673788 DOI 10.3390/ijms25084204
Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons.PubMed 40568800 DOI 10.1021/acs.jmedchem.5c00938
Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities.PubMed 40540228 DOI 10.1021/acs.jmedchem.4c03220
Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis.PubMed 40326034 DOI 10.2174/0115701638363093250324035540
The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.PubMed 36497400 DOI 10.3390/cancers14235918
Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.PubMed 42352060 DOI 10.3390/antiox15060754
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.PubMed 25269802 DOI 10.1093/carcin/bgu205
Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges.PubMed 42105814 DOI 10.1016/j.bcp.2026.118032
The Pharmacology of Cannabinoids in Chronic Pain.PubMed 40046175 DOI 10.1159/000543813
Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.PubMed 41155621 DOI 10.3390/ph18101508
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.PubMed 23415610 DOI 10.1016/j.bcp.2013.01.017
Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.PubMed 36615835 DOI 10.3390/nu15010178
Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action.PubMed 35614947 DOI 10.3389/fphar.2022.908198
Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.PubMed 36397993 DOI 10.1155/2022/3336516
Cannabichromene is a cannabinoid CB2 receptor agonist.PubMed 31368508 DOI 10.1111/bph.14815
Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy.PubMed 40790027 DOI 10.1038/s41420-025-02674-8
Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.PubMed 39137108 DOI 10.1089/can.2023.0212
The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.PubMed 23373571 DOI 10.1111/bph.12120
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes.PubMed 35628241 DOI 10.3390/ijms23105430
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.PubMed 31549358 DOI 10.1007/s40263-019-00664-w
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.PubMed 25257544 DOI 10.1111/bph.12944
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.PubMed 16205722 DOI 10.1038/sj.bjp.0706414
Pharmacology of cannabinoids in the treatment of epilepsy.PubMed 28087250 DOI 10.1016/j.yebeh.2016.11.016
Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.PubMed 41008636 DOI 10.3390/biom15091329
Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.PubMed 30170189 DOI 10.1016/j.phrs.2018.08.021
Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.PubMed 31454413 DOI 10.1111/bph.14844
Cannabinergic ligands.PubMed 12505686 DOI 10.1016/s0009-3084(02
Pharmacology of cannabinoid receptor ligands.PubMed 10469884
Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.PubMed 31968549 DOI 10.3390/molecules25020417
Synthetic Cannabinoids.PubMed 26132518 DOI 10.1097/maj.0000000000000466
Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.PubMed 40521518 DOI 10.1021/acsomega.4c11355
Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.PubMed 34050525 DOI 10.1007/s43440-021-00270-y
Endocannabinoid System: A Multi-Facet Therapeutic Target.PubMed 27086601 DOI 10.2174/1574884711666160418105339
The pharmacology of cannabinoid receptors and their ligands: an overview.PubMed 16570099 DOI 10.1038/sj.ijo.0803272
Latest advances in cannabinoid receptor agonists.PubMed 19939187 DOI 10.1517/13543770903436505
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.PubMed 31461639 DOI 10.1016/j.ejphar.2019.172628
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.PubMed 33811300 DOI 10.1007/s12272-021-01326-6
A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay.PubMed 40271066 DOI 10.3389/fphar.2025.1469986
Functional Selectivity at Cannabinoid Receptors.PubMed 28826535 DOI 10.1016/bs.apha.2017.03.005
Pharmacology of cannabinoid CB1 and CB2 receptors.PubMed 9336020 DOI 10.1016/s0163-7258(97
CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.PubMed 26124120 DOI 10.1073/pnas.1503395112
The Spicy Story of Cannabimimetic Indoles.PubMed 34684770 DOI 10.3390/molecules26206190
Crystal Structure of the Human Cannabinoid Receptor CB2.PubMed 30639103 DOI 10.1016/j.cell.2018.12.011
Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.PubMed 32004460 DOI 10.1016/j.cell.2020.01.007
Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.PubMed 28220706 DOI 10.1021/acschemneuro.7b00003
A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes.PubMed 36889269
CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.PubMed 33749323 DOI 10.1152/ajprenal.00065.2021
CB2 cannabinoid receptor-mediated peripheral antinociception.PubMed 11514083 DOI 10.1016/s0304-3959(01
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.PubMed 27215781 DOI 10.1080/13543776.2016.1193157
CB2 cannabinoid receptor mediation of antinociception.PubMed 16563625 DOI 10.1016/j.pain.2005.12.018
The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice.PubMed 36058263 DOI 10.1016/j.lfs.2022.120928
Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation.PubMed 34774714 DOI 10.1016/j.neuroscience.2021.11.007
The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats.PubMed 27608434 DOI 10.1016/j.eplepsyres.2016.08.011
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.PubMed 20849866 DOI 10.1016/j.neuropharm.2010.09.004
Structural basis of selective cannabinoid CB2 receptor activation.PubMed 36922494 DOI 10.1038/s41467-023-37112-9
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).PubMed 38886185 DOI 10.1080/13543776.2024.2368745
Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation.PubMed 37349984 DOI 10.1111/bph.16172
Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential.PubMed 36028971 DOI 10.2174/0929867329666220825161603
The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.PubMed 29980914 DOI 10.1007/164_2018_143
Structural requirements for cannabinoid receptor probes.PubMed 16596776 DOI 10.1007/3-540-26573-2_7
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.PubMed 19152719 DOI 10.1017/s1462399409000957
Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease.PubMed 38662453 DOI 10.1172/jci175205
CB₂: therapeutic target-in-waiting.PubMed 22197668 DOI 10.1016/j.pnpbp.2011.12.001
Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation.PubMed 39173999 DOI 10.1016/j.lfs.2024.123002
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.PubMed 39264450 DOI 10.1007/s00213-024-06683-w
Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.PubMed 36475439 DOI 10.1098/rspb.2022.1941
Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.PubMed 37061199 DOI 10.1016/j.bbr.2023.114439
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.PubMed 18615177 DOI 10.2174/157015907780866884
Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice.PubMed 30666359 DOI 10.1007/s00213-019-5166-y
An overview of the cannabinoid type 2 receptor system and its therapeutic potential.PubMed 29794855 DOI 10.1097/aco.0000000000000616
Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.PubMed 37286073 DOI 10.1016/j.neuropharm.2023.109601
Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.PubMed 26824325 DOI 10.18632/oncotarget.7042
CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.PubMed 23960212 DOI 10.1093/cercor/bht202
Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro.PubMed 38751621 DOI 10.1021/acsptsci.4c00014
The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.PubMed 20236042 DOI 10.2174/187152410790780145
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.PubMed 12823482 DOI 10.1046/j.1460-9568.2003.02704.x
Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.PubMed 30414958 DOI 10.1016/j.jpain.2018.10.007
Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.PubMed 36583304 DOI 10.1002/ptr.7710
A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.PubMed 41875735 DOI 10.1016/j.phymed.2026.158068
Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.PubMed 40332343 DOI 10.3390/ijms26083720
CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.PubMed 41383775 DOI 10.1101/2025.11.26.690750
What we know and do not know about the cannabinoid receptor 2 (CB2).PubMed 24877594 DOI 10.1016/j.smim.2014.04.002
Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases.PubMed 40791361 DOI 10.1101/2025.07.11.664477
Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders.PubMed 40943579 DOI 10.3390/ijms26178657
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.PubMed 16086683 DOI 10.1111/j.1471-4159.2005.03380.x
Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization.PubMed 41310604 DOI 10.1186/s12903-025-07176-8
The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.PubMed 18247131 DOI 10.1007/s11481-007-9077-z
Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?PubMed 32471272 DOI 10.3390/ijms21113809
Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling.PubMed 39538989 DOI 10.1093/jleuko/qiae246
Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.PubMed 41740200 DOI 10.1016/j.molpha.2026.100102
Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity.PubMed 35862111 DOI 10.1002/jcp.30837
GPR55 - a putative "type 3" cannabinoid receptor in inflammation.PubMed 26669245 DOI 10.1515/jbcpp-2015-0080
Cannabinoid receptor ligand bias: implications in the central nervous system.PubMed 27835801 DOI 10.1016/j.coph.2016.10.005
GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?PubMed 20370712 DOI 10.2174/156802610791164229
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD).PubMed 35083862 DOI 10.1111/bcpt.13710
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.PubMed 17704827 DOI 10.1038/sj.bjp.0707419
GPR55: a new member of the cannabinoid receptor clan?PubMed 17876300 DOI 10.1038/sj.bjp.0707464
Pharmacological characterization of GPR55, a putative cannabinoid receptor.PubMed 20298715 DOI 10.1016/j.pharmthera.2010.02.004
The orphan receptor GPR55 is a novel cannabinoid receptor.PubMed 17876302 DOI 10.1038/sj.bjp.0707460
Cannabinoids in Gynecological Diseases.PubMed 34676329 DOI 10.1159/000499164
Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders.PubMed 42114685 DOI 10.1016/j.bcp.2026.118038
Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.PubMed 29902723 DOI 10.1016/j.ejmech.2018.05.050
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors.PubMed 29098189 DOI 10.1089/can.2017.0036
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.PubMed 20346144 DOI 10.1186/1471-2202-11-44
siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration.PubMed 22834922 DOI 10.1186/1750-2187-7-10
Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.PubMed 24751709 DOI 10.1016/j.ejphar.2014.03.055
Novel cannabinoid receptors.PubMed 17906678 DOI 10.1038/sj.bjp.0707481
Endocannabinoid signaling in microglia.PubMed 36222019 DOI 10.1002/glia.24281
A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders.PubMed 26845556 DOI 10.2174/1568026616666160204121039
Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.PubMed 29470146 DOI 10.1152/ajpgi.00013.2018
Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.PubMed 41802611 DOI 10.1016/j.freeradbiomed.2026.02.059
Identification of the TRPA1 cannabinoid-binding site.PubMed 39368566 DOI 10.1016/j.phrs.2024.107444
Molecular Targets of the Phytocannabinoids: A Complex Picture.PubMed 28120232 DOI 10.1007/978-3-319-45541-9_4
G-protein coupled receptors regulating cough.PubMed 21727026 DOI 10.1016/j.coph.2011.06.005
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.PubMed 25065940 DOI 10.1016/j.bmc.2014.07.006
Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.PubMed 36150527 DOI 10.1016/j.plipres.2022.101194
Metabolism of endocannabinoids.PubMed 27516570 DOI 10.5604/17322693.1213898
The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells.PubMed 34126378 DOI 10.1016/j.plefa.2021.102311
Endocannabinoid metabolism by cytochrome P450 monooxygenases.PubMed 25461979 DOI 10.1016/j.prostaglandins.2014.11.002
Cannabinoid CB1 receptors regulate salivation.PubMed 35986066 DOI 10.1038/s41598-022-17987-2
Chemical probes of endocannabinoid metabolism.PubMed 23512546 DOI 10.1124/pr.112.006387
Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.PubMed 24768821 DOI 10.1016/j.exger.2014.04.008
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.PubMed 36966972 DOI 10.1016/j.pharmthera.2023.108394
2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice.PubMed 36125319 DOI 10.1111/acer.14949
The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity.PubMed 33450278 DOI 10.1016/j.neuropharm.2021.108450
Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids.PubMed 24676249 DOI 10.1039/c4cs00047a
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.PubMed 38052772 DOI 10.1038/s41467-023-43606-3
Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.PubMed 40563990 DOI 10.3390/biomedicines13061271
Protective effect of palmitoylethanolamide in a rat model of cystitis.PubMed 25463999 DOI 10.1016/j.juro.2014.11.083
Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.PubMed 27720681 DOI 10.1016/j.ejphar.2016.10.005
Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor.PubMed 28336953 DOI 10.1038/s41598-017-00342-1
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?PubMed 10469890
The role of the CB1 receptor in the regulation of sleep.PubMed 18514375 DOI 10.1016/j.pnpbp.2008.04.008
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.PubMed 24644287 DOI 10.1074/jbc.m113.536953
Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.PubMed 33568652 DOI 10.1038/s41467-021-20946-6
The cannabinoid receptors.PubMed 12432948 DOI 10.1016/s0090-6980(02
Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.PubMed 17698254 DOI 10.1016/j.neuint.2007.06.033
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.PubMed 15901805 DOI 10.1124/jpet.105.085282
Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.PubMed 15148262 DOI 10.1038/sj.bjp.0705789
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.PubMed 12023533 DOI 10.1124/jpet.301.3.1020
Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria.PubMed 32696508 DOI 10.1002/jcp.29949
Mechanism of platelet activation induced by endocannabinoids in blood and plasma.PubMed 23789792 DOI 10.3109/09537104.2013.803530
Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight.PubMed 30070030 DOI 10.1002/oby.22245
Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.PubMed 26707833 DOI 10.1016/j.phrs.2015.12.009
Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.PubMed 23813098 DOI 10.1007/s12035-013-8487-6

CB2 has research behind it, but the bucket matters.

What the CB2 research is usually about

CB2

CB2

CB2

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

Receptor, target, metabolic, and pharmacology mechanisms

receptor, transporter, target, metabolic, or pharmacology mechanisms

Evidence buckets before the source table

Keep reading around this topic

Read safety context beside the research guide.

CB2 Evidence Review: the long-form source walk-through

Start with the research question

Where this page has the most source density

Bucket chapters: what the literature is circling

CB2

CB2

CB2

2-AG biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

Receptor, target, metabolic, and pharmacology mechanisms

receptor, transporter, target, metabolic, or pharmacology mechanisms

anandamide biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

CB1

Human evidence, mechanisms, and safety are different lanes

What this does and does not mean

How to use the source table

Source-reading checklist for CB2

CB2 source-by-source reading notes

Source-backed evidence table and references

Plain-Language Summary

Identity

Evidence Snapshot

Key Draft Sections

Ligands And Modulators

Source-Backed Evidence Table

Related Pages

References